1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
- MORE
Global West Nile Virus Therapeutics Market: About this market
The West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.
Global West Nile Virus Therapeutics Market: Overview
Availability of over-the-counter therapeutics
West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.
Rising awareness
In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.
Competitive Landscape
With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.
Global West Nile Virus Therapeutics Market: Overview
Availability of over-the-counter therapeutics
West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.
Rising awareness
In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.
Competitive Landscape
With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Neuroinvasive - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Neuroinvasive - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-neuroinvasive - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-neuroinvasive - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. - Product segments
Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
Exhibit 53: Aurobindo Pharma Ltd. - Key customers
Exhibit 54: Bayer AG - Vendor overview
Exhibit 55: Bayer AG - Business segments
Exhibit 56: Bayer AG - Organizational developments
Exhibit 57: Bayer AG - Geographic focus
Exhibit 58: Bayer AG - Segment focus
Exhibit 59: Bayer AG - Key offerings
Exhibit 60: Bayer AG - Key customers
Exhibit 61: GlaxoSmithKline Plc - Vendor overview
Exhibit 62: GlaxoSmithKline Plc - Business segments
Exhibit 63: GlaxoSmithKline Plc - Organizational developments
Exhibit 64: GlaxoSmithKline Plc - Geographic focus
Exhibit 65: GlaxoSmithKline Plc - Segment focus
Exhibit 66: GlaxoSmithKline Plc - Key offerings
Exhibit 67: GlaxoSmithKline Plc - Key customers
Exhibit 68: Granules India Ltd. - Vendor overview
Exhibit 69: Granules India Ltd. - Business segments
Exhibit 70: Granules India Ltd. - Organizational developments
Exhibit 71: Granules India Ltd. - Geographic focus
Exhibit 72: Granules India Ltd. - Segment focus
Exhibit 73: Granules India Ltd. - Key offerings
Exhibit 74: Granules India Ltd. - Key customers
Exhibit 75: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 76: Johnson & Johnson Services Inc. - Business segments
Exhibit 77: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 78: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 79: Johnson & Johnson Services Inc. - Segment focus
Exhibit 80: Johnson & Johnson Services Inc. - Key offerings
Exhibit 81: Johnson & Johnson Services Inc. - Key customers
Exhibit 82: Mylan NV - Vendor overview
Exhibit 83: Mylan NV - Product segments
Exhibit 84: Mylan NV - Organizational developments
Exhibit 85: Mylan NV - Geographic focus
Exhibit 86: Mylan NV - Segment focus
Exhibit 87: Mylan NV - Key offerings
Exhibit 88: Mylan NV - Key customers
Exhibit 89: Novartis AG - Vendor overview
Exhibit 90: Novartis AG - Business segments
Exhibit 91: Novartis AG - Organizational developments
Exhibit 92: Novartis AG - Geographic focus
Exhibit 93: Novartis AG - Segment focus
Exhibit 94: Novartis AG - Key offerings
Exhibit 95: Novartis AG - Key customers
Exhibit 96: Perrigo Co. Plc - Vendor overview
Exhibit 97: Perrigo Co. Plc - Business segments
Exhibit 98: Perrigo Co. Plc - Organizational developments
Exhibit 99: Perrigo Co. Plc - Geographic focus
Exhibit 100: Perrigo Co. Plc - Segment focus
Exhibit 101: Perrigo Co. Plc - Key offerings
Exhibit 102: Perrigo Co. Plc - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by application
- Comparison by application
- Neuroinvasive - Market size and forecast 2018-2023
- Non-neuroinvasive - Market size and forecast 2018-2023
- Market opportunity by application
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Shifting epidemiology of Flaviviridae
- Rising awareness
- Growing risk of spreading infections via blood transfusions
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Johnson & Johnson Services Inc.
- Mylan NV
- Novartis AG
- Perrigo Co. Plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Neuroinvasive - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Neuroinvasive - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-neuroinvasive - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-neuroinvasive - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by application
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. - Product segments
Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
Exhibit 53: Aurobindo Pharma Ltd. - Key customers
Exhibit 54: Bayer AG - Vendor overview
Exhibit 55: Bayer AG - Business segments
Exhibit 56: Bayer AG - Organizational developments
Exhibit 57: Bayer AG - Geographic focus
Exhibit 58: Bayer AG - Segment focus
Exhibit 59: Bayer AG - Key offerings
Exhibit 60: Bayer AG - Key customers
Exhibit 61: GlaxoSmithKline Plc - Vendor overview
Exhibit 62: GlaxoSmithKline Plc - Business segments
Exhibit 63: GlaxoSmithKline Plc - Organizational developments
Exhibit 64: GlaxoSmithKline Plc - Geographic focus
Exhibit 65: GlaxoSmithKline Plc - Segment focus
Exhibit 66: GlaxoSmithKline Plc - Key offerings
Exhibit 67: GlaxoSmithKline Plc - Key customers
Exhibit 68: Granules India Ltd. - Vendor overview
Exhibit 69: Granules India Ltd. - Business segments
Exhibit 70: Granules India Ltd. - Organizational developments
Exhibit 71: Granules India Ltd. - Geographic focus
Exhibit 72: Granules India Ltd. - Segment focus
Exhibit 73: Granules India Ltd. - Key offerings
Exhibit 74: Granules India Ltd. - Key customers
Exhibit 75: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 76: Johnson & Johnson Services Inc. - Business segments
Exhibit 77: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 78: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 79: Johnson & Johnson Services Inc. - Segment focus
Exhibit 80: Johnson & Johnson Services Inc. - Key offerings
Exhibit 81: Johnson & Johnson Services Inc. - Key customers
Exhibit 82: Mylan NV - Vendor overview
Exhibit 83: Mylan NV - Product segments
Exhibit 84: Mylan NV - Organizational developments
Exhibit 85: Mylan NV - Geographic focus
Exhibit 86: Mylan NV - Segment focus
Exhibit 87: Mylan NV - Key offerings
Exhibit 88: Mylan NV - Key customers
Exhibit 89: Novartis AG - Vendor overview
Exhibit 90: Novartis AG - Business segments
Exhibit 91: Novartis AG - Organizational developments
Exhibit 92: Novartis AG - Geographic focus
Exhibit 93: Novartis AG - Segment focus
Exhibit 94: Novartis AG - Key offerings
Exhibit 95: Novartis AG - Key customers
Exhibit 96: Perrigo Co. Plc - Vendor overview
Exhibit 97: Perrigo Co. Plc - Business segments
Exhibit 98: Perrigo Co. Plc - Organizational developments
Exhibit 99: Perrigo Co. Plc - Geographic focus
Exhibit 100: Perrigo Co. Plc - Segment focus
Exhibit 101: Perrigo Co. Plc - Key offerings
Exhibit 102: Perrigo Co. Plc - Key customers
Exhibit 103: Pfizer Inc. - Vendor overview
Exhibit 104: Pfizer Inc. - Business segments
Exhibit 105: Pfizer Inc. - Organizational developments
Exhibit 106: Pfizer Inc. - Geographic focus
Exhibit 107: Pfizer Inc. - Segment focus
Exhibit 108: Pfizer Inc. - Key offerings
Exhibit 109: Pfizer Inc. - Key customers
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 116: Validation techniques employed for market sizing
Exhibit 117: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Mylan NV
- Novartis AG
- MORE
The following companies are recognised as the key players in the global West Nile virus therapeutics market: Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising awareness.”
According to the report, one of the major drivers for this market is the availability of over-the-counter therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the programs to control mosquito breeding.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising awareness.”
According to the report, one of the major drivers for this market is the availability of over-the-counter therapeutics.
Further, the report states that one of the major factors hindering the growth of this market is the programs to control mosquito breeding.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Aurobindo Pharma Ltd.
- Bayer AG
- GlaxoSmithKline Plc
- Granules India Ltd.
- Johnson & Johnson Services Inc.
- Mylan NV
- Novartis AG
- Perrigo Co. Plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
